AdrenoMed AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.adrenomed.com
Clinical Trials
8
Active:3
Completed:5
Trial Phases
2 Phases
Phase 1:4
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
2 (33.3%)Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
Phase 2
Completed
- Conditions
- Septic Shock
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Adrenomed AG
- Target Recruit Count
- 301
- Registration Number
- NCT03085758
- Locations
- 🇧🇪
Clinique Universitaire Saint-Luc (UCL Bruxelles), Brussels, Belgium
🇧🇪Antwerp University Hospital (UZA), Critical Care Medicine, Edegem, Belgium
🇧🇪Groupe Jolimont, Hospitalier de Jolimont, Haine Saint Paul, Belgium
Adrecizumab-LPS Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Adrenomed AG
- Target Recruit Count
- 24
- Registration Number
- NCT03083171
- Locations
- 🇳🇱
Dept. of Intensive Care Medicine, Research-unit, Radboud university medical center, Nijmegen, Gelderland, Netherlands
News
Enibarcimab Shows Promising Results in Biomarker-Guided Septic Shock Treatment
Journal of Critical Care has published positive results from AdrenoMed's Phase II AdrenOSS-2 trial, showing enibarcimab improved organ function and reduced 28-day mortality in septic shock patients.